Acridine

Acridine

SCHEMBL4854060

NC(=O)O.c1ccc2nc3ccccc3cc2c1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.68
MAPT P10636 5/20 0.68
HPGD P15428 4/20 0.68
GLA P06280 3/20 0.68
ACHE P22303 1/20 0.68
IKBKB O14920 1/20 0.58
HTR3A P46098 1/20 0.55
KDM4E B2RXH2 7/20 0.53
GAA P10253 4/20 0.53
KMT2A Q03164 3/20 0.53
RAB9A P51151 3/20 0.53
POLB P06746 2/20 0.53
NPC1 O15118 2/20 0.53
LMNA P02545 2/20 0.53
PTBP1 P26599 1/20 0.53
RCE1 Q9Y256 1/20 0.53
MGAM O43451 2/20 0.50
MEN1 O00255 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.46
NQO2 P16083 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acridine SCHEMBL28228757 0.91 ALDH1A1 (0.68) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL8643076 0.86 ALDH1A1 (0.68) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL11500721 0.86 MAPT (0.68) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL17141399 0.85 ALDH1A1 (0.83) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL27603600 0.85 ALDH1A1 (0.94) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL8079545 0.84 ALDH1A1 (0.65) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL18921100 0.84 ALDH1A1 (0.71) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL7528429 0.84 ALDH1A1 (0.71) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL618774 0.84 ALDH1A1 (0.71) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL8827903 0.83 ALDH1A1 (0.52) ALDH1A1MAPTHPGDGLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459284-B2 Chemiluminescent acridinium compounds and analogues thereof as substrates of hydrolytic enzymes SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2008-12-02 US disclosed
US-20060202179-A1 Chemiluminescent Acridinium Compounds and Analogues thereof as Substrates of Hydrolytic Enzymes BAYER CORPORATION (US) 2006-09-14 US disclosed
US-7097995-B2 Chemiluminescent acridinium compounds and analogues thereof as substrates of hydrolytic enzymes BAYER CORP. (US) 2006-08-29 US disclosed
EP-1203091-B1 CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC ENZYMES SUCH AS PHOSPHATASES BAYER AG (US) 2005-03-16 EP disclosed
US-20050032147-A1 Chemiluminescent acridinum compounds and analogues thereof as substrates of hydrolytic enzymes BAYER CORPORATION 2005-02-10 US disclosed
US-6783948-B1 USED IN DIAGNOSTIC IMMUNOASSAYS; HAS DISTINCTLY DIFFERENT LIGHT EMISSION CHARACTERISTICS (EMISSION WAVELENGTH, KINETICS, OR QUANTUM YIELD) BAYER CORPORATION 2004-08-31 US disclosed
EP-1203091-A1 CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC ENZYMES SUCH AS PHOSPHATASES Bayer Corporation (US) 2002-05-08 EP disclosed
WO-2001009372-A1 CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC ENZYMES SUCH AS PHOSPHATASES BAYER CORPORATION (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032147-A1 Chemiluminescent acridinum compounds and analogues thereof as substrates of hydrolytic enzymes MPO, LPO, PGLS ALDH1A1 118/4885MAPT 4393/4885HPGD 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.